Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades.
There is only little information about the role of mutations of the thymidine kinase (TK) and DNA polymerase (pol) genes of herpes simplex virus type 2 (HSV-2) for the development of antiviral resistance. In this study, the polymorphism of TK and DNA pol genes was examined in 82 clinical isolates collected routinely between 1973 and 2013. If novel, presently unclear or resistance-related mutations were found, the resistance phenotype against acyclovir (ACV) and foscarnet (FOS) was analyzed. The four novel amino acid changes G150D, A157T, R248W, L342W and the hitherto phenotypically unclear substitution T131M within the TK gene were identified as natural polymorphisms. Within the DNA pol gene, 17 novel substitutions and the to-date unclear change R628C were characterized as part of natural gene polymorphism. Two novel DNA pol mutations were linked to resistance (M910T) and weak susceptibility to ACV (684 insertion ED), respectively. In one isolate, the genomic cause of ACV resistance could not be identified. Phylogenetic analysis including sequences of this study and of the GenBank revealed a hierarchy of mutation clusters in TK displaying G39E as first common mutation step, followed by N78D and L140F. In conclusion, the present findings allow a deeper insight in the variability of HSV-2 TK and DNA pol genes. The most common substitution G39E can be excluded as unique cause of HSV-2 resistance. This study supports once more the importance of phenotypic adjustment of genotypic results to enhance the clinical utility of genotypic findings.
Institute of Virology and Antiviral Therapy, Consultant Laboratory for HSV and VZV, Jena University Clinic, Hans-Knoell-Strasse 2, 07745 Jena, Germany.
Kathrin
K
Bohn-Wippert
Institute of Virology and Antiviral Therapy, Consultant Laboratory for HSV and VZV, Jena University Clinic, Hans-Knoell-Strasse 2, 07745 Jena, Germany.
Susanne
S
Schmidt
Institute of Virology and Antiviral Therapy, Consultant Laboratory for HSV and VZV, Jena University Clinic, Hans-Knoell-Strasse 2, 07745 Jena, Germany.
Anna
A
Runtze
Institute of Virology and Antiviral Therapy, Consultant Laboratory for HSV and VZV, Jena University Clinic, Hans-Knoell-Strasse 2, 07745 Jena, Germany.
Roland
R
Zell
Institute of Virology and Antiviral Therapy, Consultant Laboratory for HSV and VZV, Jena University Clinic, Hans-Knoell-Strasse 2, 07745 Jena, Germany. Electronic address: Andreas.Sauerbrei@med.uni-jena.de.
Andreas
A
Sauerbrei
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000494:pharmacology*; D016000:Cluster Analysis; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D020125:Mutation, Missense; D010641:Phenotype; D010802:Phylogeny; D011110:Polymorphism, Genetic; D013937:Thymidine Kinase / Q000235:genetics; D055815:Young Adult
D000998:Antiviral Agents; D013937:Thymidine Kinase; D004259:DNA-Directed DNA Polymerase
HSV-2; Phylogenetic analysis; Resistance genotype; Resistance phenotype